Ondansetron Kabi (Ondansetron Hydrochloride Dihydrate)

Ondansetron works by selectively blocking serotonin (5‑HT3) receptors located in the central nervous system and the gastrointestinal tract. This inhibition prevents serotonin‑mediated activation of the chemoreceptor trigger zone and vagal afferents, thereby reducing the neural signals that cause nausea and vomiting.

The dose of Ondansetron Kabi is determined by the prescribing clinician based on the specific clinical situation, such as the type of chemotherapy or surgical procedure. The prescriber will select the appropriate amount, timing, and infusion rate for each patient.

Safety data for Ondansetron Kabi in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To order Ondansetron Kabi, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details (including any cold‑chain requirements) and import documentation.

Ondansetron belongs to the 5‑HT3 antagonist class, which is highly effective for chemotherapy‑induced and postoperative nausea. Compared with dopamine antagonists (e.g., metoclopramide) or corticosteroids (e.g., dexamethasone), ondansetron offers a more targeted mechanism with fewer extrapyramidal side effects, though it may carry a risk of QT prolongation.

Ondansetron Kabi should be stored at 2‑8 °C, protected from light, and kept in its original packaging. Do not freeze or shake the solution. Before administration, allow the product to reach room temperature if required, and inspect for any particulate matter or discoloration.

Ondansetron Kabi is given as an intravenous infusion. The solution is typically diluted in compatible IV fluids and administered over a few minutes, as directed by the prescriber. Administration should follow aseptic technique and be performed by qualified healthcare personnel.

The most serious risks include QT interval prolongation, which can lead to potentially fatal cardiac arrhythmias, and severe hypersensitivity reactions such as anaphylaxis. Patients with known congenital long QT syndrome or those receiving other QT‑prolonging drugs should be monitored closely.

Ondansetron Kabi should be avoided in patients with a known hypersensitivity to ondansetron or any component of the formulation, and in individuals with congenital long QT syndrome or uncontrolled electrolyte imbalances that predispose to cardiac arrhythmias.